Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
about
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerThe epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.Combination genetic signature stratifies lower-grade gliomas better than histological grade.Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerAttempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.Hypertonic saline protects brain endothelial cells against hypoxia correlated to the levels of epidermal growth factor receptor and interleukin-1β.Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migrationSomatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.HER2-positive breast cancer is lost in translation: time for patient-centered research.64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression.Metastatic breast cancer: The Odyssey of personalization.Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction.Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome.Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.Porcine epidemic diarrhea virus-induced epidermal growth factor receptor activation impairs the antiviral activity of type I interferon.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation.Effects of miR‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR.
P2860
Q28085413-1EBECEB9-7BCA-42E8-B997-23CFCE5CB4D8Q35744220-BF761750-F39E-4894-A307-2C06E620CED8Q36064912-89FDB9C5-5CF7-4F81-94B1-26E0FC00F064Q36087126-56DB90A4-A9D3-4629-8E5F-05AED2257B1BQ36356194-2085F0E9-31D1-4326-B97F-2C43B724A521Q36898399-D49839D4-74B7-45CA-9C22-5CAA1ED8F700Q37107334-1B3D1D68-9CAA-4021-95A5-CC632138285BQ37582656-B69BA88E-EE93-4D00-BF56-52E24E290281Q37641518-7BC1C197-7450-452C-8240-C2512489024EQ37687527-595B65EE-6CAA-44C4-846B-56DCCE41EF2AQ38591976-7A19B3F8-3790-4FF0-BEA2-EEE78B70D470Q38648765-4D53EEFD-5D5B-4345-BAC0-C1EA3900FE89Q38815325-C64E11A8-FE11-4ECB-B899-FDA0E7F1D633Q38834075-08E385DF-E669-4DDD-9CAA-427EB4DB2C42Q38901163-48668A51-CA32-4540-96D3-BCAB2AD862A4Q41612212-596A04B1-A64A-4B46-9E28-9B9B8721B5D5Q47130842-CBBA2AD8-C5DD-4C0F-89EB-956EA0A0D21CQ47135806-1C75982B-DA73-4A0A-9B69-A0504778CB9AQ47222376-A5738C0A-85CF-4DE3-A029-38CF13CA835BQ47547475-5D0A5F47-0FD7-425A-A808-25364F20ECFBQ48308048-AB1C2A11-C5FA-4B19-8BDB-4925DB234764Q49544289-0CF9291A-5357-4158-89D2-99E3554B11D6Q49887903-68C09655-ADBD-419A-A0C1-1EB801EC75D2Q49887925-D47F5969-30FA-4C64-B2AD-7AA5BFB0844AQ50884256-7B78C5CB-2D91-4932-A2FB-7E15BFC83701Q55113730-F18F62DC-10B4-42EE-9AFB-3ED68324B51A
P2860
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@ast
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@en
type
label
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@ast
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@en
prefLabel
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@ast
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@en
P2093
P2860
P356
P1476
Prognostic and predictive valu ...... n HER2-positive breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.556
P407
P577
2014-10-28T00:00:00Z